文献速递冠心病

Selatogrel皮下单次给药在慢性冠脉综合征患者中的药效学、药代动力学与安全性

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
PubMed 文献 · Eur Heart J · 2020-01-01

本研究为双盲随机试验,纳入345例接受口服抗血小板治疗的慢性冠脉综合征患者,比较皮下注射selatogrel 8 mg、16 mg与安慰剂的药效学与药代动力学。结果显示selatogrel起效迅速,30分钟时应答率分别为89%和90%,安慰剂为16%(P<0.0001),PRU值在15分钟时显著降低并维持<100至8小时,24小时恢复至基线附近,安全耐受。

要点

  • 皮下注射selatogrel 8 mg或16 mg在30分钟内快速抑制血小板P2Y12受体,应答率约90%。
  • PRU值在15分钟时显著降低,维持<100至8小时,24小时恢复至基线附近。
  • selatogrel安全耐受,一过性呼吸困难总体发生率为7%(16/229,95%CI 4-11%)。

核心结论

  • Selatogrel皮下给药在CCS患者中快速吸收,提供迅速、强效且一致的血小板P2Y12抑制,持续≥8小时并在24小时内可逆。

研究设计与样本

  • 双盲、随机研究,纳入345例接受背景口服抗血小板治疗的慢性冠脉综合征患者。
  • 皮下selatogrel 8 mg(n=114)或16 mg(n=115)与安慰剂(n=116)比较(NCT03384966)。

主要发现

  • 给药后30分钟,应答率:selatogrel 8 mg组89%,16 mg组90%,安慰剂组16%(P<0.0001)。
  • PRU值(均值±标准差)在15分钟时为:8 mg组10±25,16 mg组4±10,安慰剂组163±73;两剂量组维持<100至8小时,24小时恢复至基线或接近基线水平。
  • LTA数据显示相似快速强效的血小板聚集抑制。
  • Selatogrel血浆浓度在给药后约30分钟达峰。
  • 一过性呼吸困难总体发生率为7%(16/229,95%CI 4-11%)。

临床怎么用

  • 对于需要快速血小板抑制的临床场景,皮下selatogrel可能提供快速起效且可逆的抗血小板作用,但需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). METHODS AND RESULTS: In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov: NCT03384966). Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance aggregometry; LTA). Pharmacodynamic responders were defined as patients having P2Y12 reaction units (PRU) <100 at 30 min post-dose and lasting ≥3 h. At 30 min post-dose, 89% of patients were responders to selatogrel 8 mg, 90% to selatogrel 16 mg, and 16% to placebo (P < 0.0001). PRU values (mean ± standard deviation) were 10 ± 25 (8 mg), 4 ± 10 (16 mg), and 163 ± 73 (placebo) at 15 min and remained <100 up to 8 h for both doses, returning to pre-dose or near pre-dose levels by 24 h post-dose. LTA data showed similarly rapid and potent inhibition of platelet aggregation. Selatogrel plasma concentrations peaked ∼30 min post-dose. Selatogrel was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16/229) of patients (95% confidence interval: 4-11%). CONCLUSIONS: Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent, and consistent platelet P2Y12 inhibition sustained for ≥8 h and reversible within 24 h. Further studies of subcutaneous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Storey RF, Gurbel PA, Ten Berg J, et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J. 2020. PMID: 31994703. doi:10.1093/eurheartj/ehz807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。